ArticleMolecular psychiatry2022
Deep brain stimulation of the "medial forebrain bundle": sustained efficacy of antidepressant effect over years.
Article in Molecular psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06096207 (Deep Brain Stimulation), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Barriers and facilitators to implementing deep brain stimulation for psychiatric disorders: a systematic review.Translational psychiatry · 2026Pooled it
- Physical Therapy for Treatment-Resistant Depression A Comprehensive Review of Efficacy, Safety, and Evidence Grading.Neuropsychiatric disease and treatment · 2026Review
- From lobotomy to connectomics: a critical review of contemporary psychosurgery.Frontiers in psychiatry · 2026Review
- Born to act: Deferred action and desire as active inference.Cognitive, affective & behavioral neuroscience · 2025Review
- Challenges and opportunities of acquiring cortical recordings for chronic adaptive deep brain stimulation.Nature biomedical engineering · 2025Review
- Deep Brain Stimulation in the Bed Nucleus of Stria Terminalis and Medial Forebrain Bundle in Two Patients With Treatment-Resistant Depression and Generalized Anxiety Disorder-A Long-Term Follow-Up.Clinical case reports · 2025Article
- Article
- Deep brain stimulation for refractory major depressive disorder: a comprehensive review.Molecular psychiatry · 2024Review
- Opportunities and challenges for the use of deep brain stimulation in the treatment of refractory major depression.Discover mental health · 2024Review
- Deep Brain Stimulation (DBS) in Treatment-Resistant Depression (TRD): Hope and Concern.Advances in experimental medicine and biology · 2024Review
- Are we getting closer to offering deep brain stimulation for treatment-resistant depression in clinical practice?Molecular psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep brain stimulation (DBS) to the superolateral branch of the medial forebrain bundle (MFB) has emerged as a quite efficacious therapy for treatment resistant depression (TRD), leading to rapid antidepressant effects. In this study, we complete our assessment of our first 10 enrolled patients throughout one year post-implantation, showing sustained antidepressant effect up to 5 years. The primary outcome measure was a 50% reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score, which was interpreted as a response. Deterministic fiber tracking was used to individually map the target area. An insertional effect was seen during the 4-week sham stimulation phase (29% mean MADRS reduction, p = 0.02). However, after 2 weeks of initiating stimulation, five patients met response criteria (47% mean MADRS reduction, p < 0.001). One patient withdrew from study participation at 6 weeks. Twelve weeks after initiating stimulation, six of nine remaining patients had a >50% decrease in MADRS scores relative to baseline (52% mean MADRS reduction, p = 0.001); these same six patients continued to meet response criteria at 52 weeks (63% overall mean MADRS reduction, p < 0.001). Four of five patients who achieved the 5-year time point analysis continued to be responders (81% mean MADRS reduction, p < 0.001). Evaluation of modulated fiber tracts reveals significant common prefrontal/orbitofrontal connectivity to the target region in all responders. Key points learned from this study that we can incorporate in future protocols to better elucidate the effect of this therapy are a longer blinded sham stimulation phase and use of scheduled discontinuation concomitant with functional imaging.
Indexed as
Identifiers
35288633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.